SENTINEL DIAGNOSTICS LAUNCHES A TOTALLY AUTOMATED HIGH THROUGHPUT ANALYZER FOR FECAL IMMUNOCHEMICAL TESTING

To fulfill the growing need of Colorectal Cancer Screening organizations and big clinical laboratories, Sentinel Diagnostics - an Italian company focused for more than 35 years on the development and production of In Vitro Diagnostics for the most advanced Clinical Chemistry, Immunochemistry and Molecular Diagnostics platforms - announces the launch of the SENTiFIT(R) 8Colorectal CancerColorectal Cancer Analyzer, a fully automated and high throughput system for Fecal Immunochemical Test.

Colorectal Cancer (CRC) is one of the most dangerous and lethal cancers.  It represents the second leading cause of cancer related death in the western world with almost 2 million of new cases/year and 0.9 million deaths (www.iarc.fr). If early diagnosed, CRC is curable in most of the cases, therefore most countries organize national or regional screenings to identify the cancers in their early stage, making the cure more efficient and thus considerably decreasing mortality. Those screening programs are testing millions of people every year and this creates new challenges in the practical organization of the laboratories. The new high throughput analyzer SENTiFIT(R) 800 can meet the need of throughput, automation and accuracy of the most demanding situation.

"For almost 20 years, Sentinel Diagnostics has supported the fight against colorectal cancer with high quality FOB Gold(R) test and analyzers," explains Marco Buonaguidi, Head of Sales and Marketing. "The SENTiFIT(R) 800 has been developed specifically for FIT screening centers and represents a step further in the direction to strengthen our commitment in the field of gastrointestinal diseases diagnosis".

The SENTiFIT(R) 800 Analyzer is a high-end system dedicated to fecal testing able to process up to 550 test/h, 1 million tests every year samples in total automation and full traceability. It delivers a relevant reduction of hands-on time, better management of resources and decreasing of manual errors. The system is fed by a dedicated sample loader (Rack Handler RH-150) that provides a steady flow of up to 250 samples to the analyzer unit.

The CE-marked SENTiFIT(R) 800 Analyzer is compatible with the FOB Gold(R) line, the complete solution for the identification of occult blood in feces, and with the CALiaGold(R) line reagents for the quantification of fecal Calprotectin, the first-choice test to identify the presence of inflammation in the bowel. 

Logo - https://mma.prnewswire.com/media/1839956/Sentinel_Diagnostics_Logo.jpg


ข่าวColorectal Cancer+o:editorวันนี้

"บีจีไอ" เผยผลการสำรวจเกี่ยวกับมะเร็งลำไส้ใหญ่ทั่วโลก พบช่องว่างด้านความตระหนักรู้และความกังวลเรื่องค่าใช้จ่าย

บีจีไอ จีโนมิกส์ (BGI Genomics) ได้เผยแพร่รายงานสถานการณ์ความตระหนักรู้เกี่ยวกับโรคมะเร็งลำไส้ใหญ่ (State of Colorectal Cancer Awareness Report) เพื่อสำรวจทัศนคติและความท้าทายใหญ่หลวงที่สุดเกี่ยวกับความตระหนักรู้และการตรวจคัดกรองมะเร็งลำไส้ใหญ่ (CRC) นับเป็นรายงานฉบับแรกที่ดำเนินการสำรวจระดับโลกเกี่ยวกับโรคมะเร็งชนิดที่พบมากที่สุดเป็นอันดับสามของโลกอย่างโรคมะเร็งลำไส้ใหญ่นี้ รายงานดังกล่าวนี้เผยแพร่ในวันอนามัยโลก (World Health Day) ในวันที่ 7 เมษายน 2566 โดยสอดคล้องกับการมุ่งบรรลุ

To uncover attitudes and the biggest chal... BGI Global Colorectal Cancer Survey Reveals Awareness Gaps and Affordability Concerns — To uncover attitudes and the biggest challenges facing colorectal ...

COLOTECT - Non-invasive Colorectal Cancer Screening Test has been launched in Southeast Asia

COLOTECT is a non-invasive colorectal cancer (CRC) self-sampling test that can detect the methylation status of exfoliated cell genes in the intestine, help screen for colorectal cancer and precancerous...

SENTINEL DIAGNOSTICS LAUNCHES A TOTALLY AUTOMATED HIGH THROUGHPUT ANALYZER FOR FECAL IMMUNOCHEMICAL TESTING

To fulfill the growing need of Colorectal Cancer Screening organizations and big clinical laboratories, Sentinel Diagnostics - an Italian company focused for more than 35 years on the...

ผลวิจัยใหม่ชี้ การตรวจวินิจฉัยโรคมะเร็งลำไส้ใหญ่ลดลงกว่า 40% ในช่วงโควิด-19 ระบาด

ผลวิจัยใหม่ที่นำเสนอในวันนี้ที่งาน UEG Week Virtual 2021 เผยให้เห็นว่า จำนวนผู้ป่วยที่ได้รับการตรวจวินิจฉัยโรคมะเร็งลำไส้ใหญ่ (Colorectal Cancer (CRC)) ลดลงอย่างมากถึง 40% ในปีที่มีการแพร่ระบาดของโควิด-19 การวิจัยดำ...

Patients with Colorectal Cancer Liver Metastases Had Significantly Greater Depth of Tumour Response to SIR-Spheres(R) Y-90 resin microspheres, New SIRFLOX Analysis Shows

New data presented by Prof. Dr. Volker Heinemann in an oral abstract session at the European Society of Medical Oncology's 18th...

Results of Pivotal TAILOR Study Confirm Addition of Erbitux to FOLFOX Significantly Improves Outcomes in RAS Wild-Type Metastatic Colorectal Cancer

Not intended for UK- or US-based media WCGC Abstract # 0-025; poster presentation, July 1, 2016, 10:35 am CEST Phase III study shows response rate of 61...

Hetero Launches Biosimilar 'Bevacizumab' for the Treatment of Metastatic Colorectal Cancer (mCRC) Under the Brand Name 'Cizumab(TM)'

Hetero, one of India's leading generic pharmaceutical companies, today announces the launch of Biosimilar 'Bevacizumab' in India for the treatment of metastatic...

Merck and Sysmex Inostics Receive CE Mark Approval for Liquid Biopsy test for Colorectal Cancer Patients

- Novel liquid biopsy RAS testing now available to clinical practices for metastatic colorectal cancer (mCRC) patients - The test will help guide physicians to select the most effective treatment...

Taiho's TAS-102 Meets Primary Endpoint of Improving Overall Survival in Phase III TERRA Study in Asian Patients with Refractory Metastatic Colorectal Cancer

Taiho Pharmaceutical Co., Ltd. of Tokyo announced on April 1 results from its Phase III TERRA study on its oral combination anticancer drug TAS...